Results 81 to 90 of about 12,566,431 (163)

Genetic variation of rs438601 marker in the Iranian Population: An informative marker for molecular diagnosis of hemophilia B

Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, 2014
Introduction: Hemophilia B is an X-linked recessive genetic disease caused by mutations in the coagulation Factor IX gene. Mutations in the Factor IX gene result in dysfunction or deficiency of coagulation factor of IX.
P Dorri, A Karimi , S Vallian boroujeni
doaj  

Retracted: Long Intergenic Nonprotein Coding RNA 00174 Aggravates Lung Squamous Cell Carcinoma Progression via MicroRNA-185-5p/Nuclear Factor IX axis. [PDF]

Biomed Res Int, 2023
International BR.
europepmc   +1 more source

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy. [PDF]

Blood Adv, 2023
von Drygalski A, Gomez E, Giermasz A, Castaman G, Key NS, Lattimore SU, Leebeek FWG, Miesbach WA, Recht M, Gut R, Dolmetsch R, Monahan PE, Le Quellec S, Pipe SW.   +13 more
europepmc   +1 more source

The mechanism underlying activation of factor IX by factor XIa.

Thrombosis Research, 2014
D. Gailani, Yipeng Geng, I. Verhamme, Mao-fu Sun, S. P. Bajaj, A. Messer, J. Emsley   +6 more
semanticscholar   +1 more source

Blood Coagulation Factor IX: Structure, Function, and Regulation. [PDF]

IUBMB Life
Ivanciu L, Camire RM.
europepmc   +1 more source

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. [PDF]

Blood Adv, 2023
Shapiro AD, Kulkarni R, Ragni MV, Chambost H, Mahlangu J, Oldenburg J, Nolan B, Ozelo MC, Foster MC, Willemze A, Barnowski C, Jain N, Winding B, Dumont J, Lethagen S, Barnes C, Pasi KJ.   +16 more
europepmc   +1 more source

Characteristics and Treatment Patterns of Patients with Haemophilia B Receiving Recombinant Coagulation Factor IX. [PDF]

J Clin Med
Park YS, Hwang TJ, Park SK, Choi EJ, Park JA, Baek HJ, Lyu CJ, Lee JH, Kim MK, Kim JY, Lee SA, Park B, Kim DH, Chung SB, Nam CM, Lee Y, Yoo KY.   +16 more
europepmc   +1 more source

Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies. [PDF]

Blood Adv, 2023
Foley JH, Shehu E, Riddell A, Gray E, Goodale A, Yu IM, Verhoef D, Little J, Shattock D, Kitchen S, Chowdary P, Corbau R, Nathwani AC.   +12 more
europepmc   +1 more source

Extravascular factor IX after gene therapy in hemophilia B, does it matter? [PDF]

Res Pract Thromb Haemost
Van Thillo Q, Hermans C.
europepmc   +1 more source

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand. [PDF]

Res Pract Thromb Haemost, 2023
Álvarez-Román MT, Shapiro AD, Ragni MV, Palmborg H, Bystrická L, Szamosi J, Casiano S, Chambost H.   +7 more
europepmc   +1 more source